Moderate

Ulcerative colitis — maintenance & biologic therapy

UC maintenance · Gastroenterology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

After induction of remission, UC requires ongoing therapy to maintain steroid-free remission and prevent colectomy. Choice escalates from 5-ASA to immunomodulators and advanced (biologic/small-molecule) agents by disease extent and severity.

Red flags

  • Increasing frequency/bleeding despite therapy (flare)
  • Fever and systemic upset (infection/CMV)
  • Features of acute severe colitis (needs admission)
  • Dysplasia or mass on surveillance

Assessment

Differential diagnosis

  • Crohn's colitis
  • Infective colitis (reactivation)
  • C. difficile superinfection
  • CMV colitis in refractory disease
  • Irritable bowel overlap
  • Bile acid diarrhoea post-colectomy

Investigations

  • Faecal calprotectin for non-invasive monitoring
  • FBC, CRP, albumin, U&E, LFTs
  • Colonoscopy for mucosal healing and dysplasia surveillance
  • Thiopurine metabolites (TPMT/NUDT15) before azathioprine
  • Therapeutic drug monitoring of biologics
  • Hepatitis B/C, TB and VZV screen before immunosuppression

Management

  • Confirm UC extent (proctitis, left-sided, extensive) — this drives choice and route
  • Maintain mild-moderate disease with oral ± topical 5-ASA; optimise dose and adherence
  • Use topical mesalazine for proctitis/distal disease
  • Escalate steroid-dependent/refractory disease to a thiopurine or advanced therapy
  • Start a biologic or small molecule (anti-TNF, vedolizumab, ustekinumab, JAK inhibitor, S1P modulator) per severity/comorbidity
  • Complete pre-biologic infection screening (hepatitis B/C, TB, VZV) and vaccinate
  • Avoid NSAIDs and treat intercurrent infection promptly
  • Target steroid-free clinical plus biochemical remission (treat-to-target with calprotectin)
  • Monitor for drug toxicity and check therapeutic levels in secondary loss of response
  • Enrol in colonoscopic dysplasia surveillance from 8–10 years of extensive colitis
  • Give bone protection and vaccination; coordinate with colorectal surgery for refractory disease

Drugs & doses

Mesalazine 2.4–4.8 g PO daily (maintenance ≥2 g/day)
Mesalazine 1 g PR suppository/enema (distal disease)
Azathioprine 2–2.5 mg/kg PO once daily
Infliximab 5 mg/kg IV at 0, 2, 6 weeks then 8-weekly
Vedolizumab 300 mg IV induction then 8-weekly
Tofacitinib 10 mg PO twice daily induction then 5 mg twice daily

Disposition

Specialist IBD clinic with nurse-led monitoring; surgical MDT for refractory/dysplastic disease.

Complications & pitfalls

  • Acute severe colitis / toxic megacolon
  • Colorectal dysplasia and cancer
  • Drug toxicity (myelosuppression, hepatotoxicity, infection)
  • Steroid dependence and osteoporosis
  • Thromboembolism during active disease

Exam pearls

  • Maintenance 5-ASA at an adequate dose reduces both relapse and colorectal cancer risk
  • Add topical therapy to oral 5-ASA for better distal mucosal healing
  • Check TPMT/NUDT15 before thiopurines to avoid severe myelosuppression
  • Treat to a target of mucosal/biochemical healing, not just symptom control

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.